OSIRIS THERAPEUTICS,INC. (OTCMKTS:OSIR) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

63

OSIRIS THERAPEUTICS,INC. (OTCMKTS:OSIR) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Appointment of Chief Financial Officer

On May 19, 2017, Osiris Therapeutics, Inc. (the “Company”) announced the appointment of Linda Chang, age 51, as Chief Financial Officer, effective May 17, 2017. Ms. Chang was most recently Senior Vice President, Chief Financial Officer of Therabron Therapeutics from December 2015 to February 2017 where she led the Finance, Strategic Planning and Legal functions. Previously, Ms. Chang served as Senior Vice President, Chief Financial Officer, Treasurer and Corporate Secretary at PharmAthene Inc., a NYSE-MKT listed company from November 2011 until April 2015. While there, Ms. Chang was responsible for all financial operations including corporate accounting, SEC reporting, tax, treasury, financial planning, investor relations and capital access. Prior to PharmAthene, Ms. Chang held roles of increasing responsibility in the financial groups at Human Genome Sciences, Booz Allen & Hamilton, Grant Thornton LLC and Otsuka America Pharmaceuticals.

Ms. Chang has over 20 years of finance and executive leadership experience. She holds a B.S. in Business Administration from the University of California, Riverside, an M.B.A. as well as a Master of Accountancy degree from the University of Georgia. She is also Certified Public Accountant (inactive).

Ms. Chang will receive an annual base salary of $320,000 and will be entitled to earn an annual performance-based bonus opportunity of up to 25% of her base salary. In addition, Ms. Chang will be entitled to participate in a long-term incentive plan to be designed by the Compensation Committee by or before December 31, 2017. In the event of a change in control of the Company any grants or awards under the long-term incentive plan shall immediately become vested. Ms. Change will be entitled to receive a severance payment equal to six months of her annual base salary if she is terminated without cause. She will also be entitled to participate in other benefit plans generally available to other employees of the Company.

Departure of Chief Financial Officer

On May 15, 2017, the Company notified Gregory I. Law, the Company’s former Chief Financial Officer, that the Company had hired Ms. Chang as his successor. Mr. Law’s separation date is May 31, 2017. The Company has agreed to pay Mr. Law his base salary, payable in accordance with the Company’s normal payroll schedule, until August 22, 2017. Mr. Law has also agreed to provide transition assistance to the Company during the severance period and thereafter, if necessary, on a limited consulting basis.


About OSIRIS THERAPEUTICS, INC. (OTCMKTS:OSIR)

Osiris Therapeutics, Inc. is a cellular and regenerative medicine company. The Company is focused on researching, developing and marketing products in the wound, orthopedic, and sports medicine markets. The Company operates through Biosurgery business segment, which focuses on products for wound care, orthopedics, and sports medicine to harness the ability of cells and novel constructs to promote the body’s natural healing. The Company’s products include Grafix, Stravix, TruSkin, Cartiform and BIO4. The Company produces and distributes Grafix for acute and chronic wounds; Stravix for tendon repair; TruSkin for wound closure; Cartiform, a viable cartilage mesh for cartilage repair, and BIO4 for bone growth. The Company’s BioSmart cryopreservation process retains the native characteristics and inherent functionality of tissue. Its BioSmart process includes preservation of the three dimensional (3D) matrix, endogenous growth factors, and tissue-resident cells.

OSIRIS THERAPEUTICS, INC. (OTCMKTS:OSIR) Recent Trading Information

OSIRIS THERAPEUTICS, INC. (OTCMKTS:OSIR) closed its last trading session up +0.02 at 5.95 with 2,921,453 shares trading hands.

An ad to help with our costs